Augtyro (repotrectinib) — Medica
Pediatric diffuse high-grade gliomas (NTRK gene fusion-positive)
Initial criteria
- Patient is age < 18 years
- Tumor is positive for NTRK gene fusion
- Medication is used as adjuvant therapy OR medication is used for recurrent or progressive disease
Approval duration
1 year